tiprankstipranks
Trending News
More News >
C-Rad AB Class B (DE:24C)
FRANKFURT:24C

C-Rad AB Class B (24C) Price & Analysis

Compare
3 Followers

24C Stock Chart & Stats


---

Financials

Options Prices

Currently, No data available
---

Ownership Overview

0.02%99.98%
Insiders
0.02%
Mutual Funds
― Other Institutional Investors
99.98% Public Companies and
Individual Investors

24C FAQ

What was C-Rad AB Class B’s price range in the past 12 months?
C-Rad AB Class B lowest stock price was €2.25 and its highest was €4.16 in the past 12 months.
    What is C-Rad AB Class B’s market cap?
    C-Rad AB Class B’s market cap is €97.38M.
      When is C-Rad AB Class B’s upcoming earnings report date?
      C-Rad AB Class B’s upcoming earnings report date is Jul 18, 2025 which is in 68 days.
        How were C-Rad AB Class B’s earnings last quarter?
        C-Rad AB Class B released its earnings results on May 07, 2025. The company reported -€0.022 earnings per share for the quarter, missing the consensus estimate of €0.028 by -€0.05.
          Is C-Rad AB Class B overvalued?
          According to Wall Street analysts C-Rad AB Class B’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does C-Rad AB Class B pay dividends?
            C-Rad AB Class B does not currently pay dividends.
            What is C-Rad AB Class B’s EPS estimate?
            C-Rad AB Class B’s EPS estimate is 0.05.
              How many shares outstanding does C-Rad AB Class B have?
              C-Rad AB Class B has 32,904,050 shares outstanding.
                What happened to C-Rad AB Class B’s price movement after its last earnings report?
                C-Rad AB Class B reported an EPS of -€0.022 in its last earnings report, missing expectations of €0.028. Following the earnings report the stock price went down -6.122%.
                  Which hedge fund is a major shareholder of C-Rad AB Class B?
                  Currently, no hedge funds are holding shares in DE:24C
                  ---

                  Company Description

                  C-Rad AB Class B

                  C-Rad AB (publ), together with its subsidiaries, develops, manufactures, and sells systems with applications in radiation therapy for the treatment of cancer worldwide. The company operates through two segments, Positioning and Imaging. Its products include Sentinel 4D CT, a laser-based optical surface scanning system; Catalyst, a 4D surface image guided radiation therapy (SIGRT) solution; Catalyst HD, an SIGRT solution on stereotactic radiation therapy for online patient tracking before and during treatment delivery; Catalyst+, an SIGRT solution for high precision patient positioning, intra-fraction motion management, and respiratory gating; and Catalyst+ HD, a solution for high precision patient positioning, intra-fraction motion management, and respiratory gating for conventional and stereotactic treatment delivery. The company's products also comprise Catalyst Tomo, an enhanced positioning solution for tomotherapy; Catalyst PT, a real-time tracking solution for particle therapy; Cyrpa laser positioning products; cAccessory, which automates the registration and validation of treatment accessories; and cPatient that automates patient identity validation without the need for contact between patients and devices. In addition, it offers installation, application training, and aftersales services. C-Rad AB (publ) was founded in 2004 and is headquartered in Uppsala, Sweden.
                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Integrum AB Class B
                  Acarix AB
                  Sedana Medical AB
                  Mentice AB
                  Popular Stocks
                  ---
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis